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Introduction: COVID-19 has a less severe course in children. In April 2020, some
children presented with signs of multisystem inflammation with clinical signs overlapping
with Kawasaki disease (KD), most of them requiring admission to the pediatric intensive
care unit (PICU). This study aimed to describe the prevalence and clinical characteristics
of KD SARS-CoV-2 confirmed and negative patients during the pandemic in Spain.
Material and Methods: Medical data of KD patients from January 1, 2018 until May
30, 2020 was collected from the KAWA-RACE study group. We compared the KD
cases diagnosed during the COVID-19 period (March 1–May 30, 2020) that were either
SARS-CoV-2 confirmed (CoV+) or negative (CoV–) to those from the same period during
2018 and 2019 (PreCoV).
Results: One hundred and twenty-four cases were collected. There was a
significant increase in cases and PICU admissions in 2020 (P-trend = 0.001 and
0.0004, respectively). CoV+ patients were significantly older (7.5 vs. 2.5 yr) and
mainly non-Caucasian (64 vs. 29%), had incomplete KD presentation (73 vs.
32%), lower leucocyte (9.5 vs. 15.5 × 109) and platelet count (174 vs. 423
× 109/L), higher inflammatory markers (C-Reactive Protein 18.5vs. 10.9 mg/dl)
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and terminal segment of the natriuretic atrial peptide (4,766 vs. 505 pg/ml), less aneurysm
development (3.8 vs. 11.1%), and more myocardial dysfunction (30.8 vs. 1.6%) than
PreCoV patients. Respiratory symptomswere not increased during the COVID-19 period.
Conclusion: The KD CoV+ patients mostly meet pediatric inflammatory multisystem
syndrome temporally associated with COVID-19/multisystem inflammatory syndrome in
children criteria. Whether this is a novel entity or the same disease on different ends of
the spectrum is yet to be clarified.
Keywords: Kawasaki disease (KD), children, SARS-CoV-2, COVID-19, shock, multisystem inflammatory syndrome
in children (MIS-C), pediatric inflammatory multisystem syndrome (PIMS-TS)
INTRODUCTION
The epidemic of severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2), causing COVID-19, has spread rapidly around
the globe (1). Spain was one of the first European countries to be
affected after Italy, with the outbreak estimated to have started in
February 2020.
In contrast with adults, the disease in children appears to have
a less severe course, with almost no fatalities, and those reported
weremainly in children with severe underlining conditions (2, 3).
But in April, some children presented critically ill with fever,
shock, and signs of multisystem inflammation most of them
requiring admission to the pediatric intensive care unit (PICU).
They presented clinical signs overlapping with Kawasaki disease
(KD) (4, 5) triggering alerts to pediatricians. Following the alert,
theWorld Health Organization (WHO) (6), the European Centre
for Disease Prevention and Control (7), the US Centers for
Disease Control and Prevention (8), and the Royal Collage of
Paediatrics and Child Health (9) have all produced definitions
for this new entity. It was called pediatric inflammatory
multisystem syndrome temporally associated with SARS-CoV-2
infection (PIMS-TS) (9) or multisystem inflammatory syndrome
in children (MIS-C) (8) and case definition and guidance on
clinical management was published.
The cause of KD remains unknown; however, it is suggested
that an infectious agent might trigger the illness (10). A small
proportion of KD patients present with Kawasaki disease shock
syndrome (KDSS) resembling PIMS-TS/MIS-C (11). Cases of
KD with concurrent COVID-19 infection were reported (12)
suggesting that SARS-CoV-2 may trigger a cytokine storm
leading to this newly defined syndrome (13–16).
This study aimed to compare the prevalence and features of
KD patients before SARS-CoV-2 pandemic and compare them to




During 2015 a nationwide KD study group named KAWA-RACE
was setup. Patients were included retrospectively from 2011
through 2016 and prospectively from 2018 onward, based on
declaration from pediatricians of recruiting centers. A total of 93
Spanish hospitals joined the network. Our study complies with
the Declaration of Helsinki and the ethics committee at Instituto
de Investigación Hospital 12 de Octubre approved this study
(CEIC 15/316). The inclusion of patients with KD was approved
following informed consent from parents/guardians. All patient
data were fully anonymized before we accessed them, and then
the database was reviewed to clean inconsistencies and confirm
patients’ diagnoses based on information provided.
Data Source, Collection, and Management
Prospective medical data was included from January 1, 2018 until
May 30, 2020. A research electronic database capture (17) was
created and sent to the participant clinicians together with the
study protocol.
We established the date of March 1, 2020 as SARS-CoV-2
exposed cases, collected cases until May 30, 2020, and considered
this COVID-19 period (CoV-19p). The patients’ demographic,
clinical, laboratory, and echocardiographic data were recorded.
Subjects and Case Definitions
Individual patient data were reviewed to confirm the diagnosis
of complete or incomplete KD according to the American Heart
Association (AHA, 2017) (18). Coronary arteries measurements
followed Z-score of Montreal scale (19), and the classification
according to the Z-score followed AHA guidelines (18); coronary
artery lesions (CAL) were considered if the Z-score > 2, and
cardiac dysfunction was considered if ejection fraction was<55%
(20). All patients <16 years of age diagnosed with KD were
included in the study. We looked at the SARS-CoV-2-positive
patients to see if they fulfilled the WHO definition of MIS-C
(8) and/or the Royal College of Pediatrics and Child Health
definition of PIMS-TS (9).
Two groups were established for comparison. We compared
the KD cases diagnosed during the same period of 2018 and
2019 (PreCoV) to those during CoV-19p that were SARS-CoV-2
negative confirmed by both polymerase chain reaction (PCR) and
serology (CoV-) and to those during CoV-19p that were SARS-
CoV-2 confirmed with either PCR and/or serology (CoV+).
To assess the prevalence, we compared the same periods
of 2018, 2019, and 2020 (March 1, 2020–May 30, 2020). We
excluded patients older than 16 years at the time of diagnosis,
those patients diagnosed from January 1 to February 29, 2020,
because the virus could be circulating undetected, but tests were
not routinely performed and patients in whom PCR and serology
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FIGURE 1 | Trend in Kawasaki disease cases and PICU admissions from 1st March to 30th May during 2018–19 (preCoV-19p) and 2020 (CoV-19p).
were not performed. Therefore, we could not assure they were
SARS-CoV-2 negative.
Statistical Analysis
Baseline characteristics were described through summary
tables reporting frequencies and total records in case of
categorical variables and median [interquartile range (IQR)]
when continuous. Chi-squared and Fisher-test (low cell sizes< 5)
were applied to assess differences among periods for categorical
variables. For continuous variables, the non-parametric U-
Mann-Whitney test was applied. Normality was tested with
the Shapiro-Wilk test. The incidence was estimated using the
incidence R package (21), and trend was calculated using the
Chi-squared test. R software was used for all analysis (22).
RESULTS
Nationwide, 124 cases were collected during the periods March
1–May 30, 2018/19/20 with 23 (19%) requiring PICU; the
diagnosis of KD was confirmed for all patients after individual
data review. There was a significant increase in cases and PICU
admissions in 2020 (P-trend = 0.001 and 0.0004, respectively)
(Figure 1).
For comparison with the CoV– and CoV+ groups, we
excluded 15 patients in whom PCR and serology were not
performed, and therefore we could not assure they were SARS-
CoV-2 negative, leaving 109 patients included for further
analysis−63 in PreCoV group, 26 CoV+, and 20 CoV–. In the
CoV+ group, SARS-CoV-2 PCR was positive in 42% (11/26);
SARS-CoV-2 serology was positive in 100% (21/21) of patients
that had the test performed, and both were positive in 29% (n =
6). All the patients in the CoV- group had a SARS-CoV-2 PCR
and serology performed that were both negative (Tables 1, 2).
Clinical Characteristics (Table 3)
The median PreCoV age was 2.55 (IQR, 1.5–3.9), 3.56 (IQR,
2.2–6.4) for CoV– and significantly higher 7.54 (IQR, 5.4–10.8)
for CoV+ patients (p < 001). There was a male predominance
PreCoV (62%) and in CoV+ (69%) with a 1:1 ratio in CoV-
patients. We found that in PreCoV and CoV– patients, around
one-fourth of them were non-Caucasian (18/63, 29%, and 5/20,
25%, respectively), while in CoV+ patients this was significantly
higher (16/26, 64%). The median duration of fever was 7 days in
all groups.
Complete KD was less frequent during the CoV-19p [(CoV–
8/20, 40%) and (CoV+ 7/26, 27%) vs. PreCoV (43/63, 68%)]. Of
note during the CoV-19p, especially in the CoV+ group, up to
23% of patients were suspected and treated as KD but did not
fulfill AHA criteria (complete or incomplete), while during the
PreCoV this did not happen. Patients from CoV-19p who did
Frontiers in Pediatrics | www.frontiersin.org 3 January 2021 | Volume 8 | Article 617039
Fernández-Cooke et al. Kawasaki Disease in COVID-19 Times









Positive result (non-SARS-CoV-2) 17 (27%) 3 (15%) 0.227 4 (20.0%) 0.659
Coronavirus PCR performed – 26 (100%) 20 (100%)
Positive – 11 (42.3%) 0 (0.00%)
Coronavirus Serology performed – 21 (80.8%) 20 (100%)
Positive – 21 (100%)* 0 (0.00%)













< 0.001 13.8 (8.98;
21.7)
0.434
Platelets at admission 423 (301; 538) 174 (118; 250) < 0.001 294 (232; 423) 0.024
Platelets (min) 371 (284; 446) 174 (118; 250) < 0.001 290 (193; 423) 0.125




































































Fibrinogen 597 (534; 680) 810 (518; 930) 0.289 591 (523; 619) 0.605
Ferritin 185 (128; 247) 476 (358; 966) < 0.001 153 (116; 588) 0.479
#This p-value compares 2018–2019 with 2020 (CoV–). *Not tested in 5 patients. CoV+, SARS-CoV-2 positive patients; CoV–, SARS-CoV-2 negative patients; ESR, Erythrocyte
sedimentation rate; ALT, Alanine transaminase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transpeptidase; NT-proBNP, N-terminal pro b-type natriuretic peptide; IL-6,
Interleukin 6.
not fulfill AHA criteria when treatment was administered, finally
fulfilled criteria for incomplete KD.
Patients CoV+ presented with significantly fewer lips and oral
changes than PreCoV patients (85 vs. 50%, p< 0.005). No patient
in the CoV+ group had sterile pyuria while it was observed
in 21% of PreCoV and 35% of CoV– patients. Respiratory
symptoms were not increased during COV-19p, and although
it was more likely to have an abnormal chest X-ray in the
CoV+ group, this was not significant. Overall, gastrointestinal
symptoms were observed in 57% PreCoV vs. 65% in CoV+
and 55% CoV– with an increased proportion of patients with
abdominal pain in the CoV+ group (33 vs. 58% and 30%).
Irritability was significantly lower in the CoV+ group. Shock that
was not related to IVIG infusion was observed in an increased
number of patients during the CoV-19p (CoV– 4/20, 20%, and
CoV+ 13/26,50%, P < 0.001) vs. 1.6% of patients during the
PreCoV. Twenty-three (88.5%) of the CoV+ patients fulfilled
both PIMS-TC and MIS-C criteria; from the CoV– cohort, 45%
of patients fulfilled the criteria for MIS-C, and 40% for PIMS-
TS, assuming all these patients would have had exposure to
SARS-CoV-2 during this period, which is not recorded in the
database (Tables 4A, B).
There were no meaningful differences in blood results
between PreCoV and CoV– patients. Nevertheless, when
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1 (–) 1 (–) (+) Not tested
2 (–) 2 (–) (–) (+)
3 (–) 3 EBV & CMVd (+) Not tested
4 Enterovirusb 4 (–) (+) (+)
5 (–) 5 (–) (+) Not tested
6 (–) 6 (–) (–) (+)
7 Metapneumo &
coronavirusa
7 (–) (–) (+)
8 (–) 8 (–) (–) (+)
9 (–) 9 (–) (–) (+)
10 (–) 10 (–) (–) (+)
11 (–) 11 (–) (–) (+)
12 Salmonellac 12 (–) (+) (+)
13 (–) 13 (–) (+) (+)
14 (–) 14 (–) (–) (+)
15 (–) 15 (–) (–) (+)
16 (–) 16 (–) (–) (+)
17 (–) 17 (–) (–) (+)
18 (–) 18 (–) (–) (+)
19 (–) 19 CMV & EBV in blood (+) (+) Not tested
20 (–) 20 (–) (–) (+)
21 (–) 21 Anti-HBc, & anti-HBs (+) (+) Not tested
22 (–) 22 (–) (–) (+)
23 (–) 23 (–) (–) (+)
24 (–) 24 (–) (+) (+)
25 (–) 25 (–) (+) (+)
26 (–) 26 (–) (+) (+)
27 (–) SARS-COV-2 NEGATIVE
28 (–) 27 (–) (–) (–)
29 (–) 28 Mycoplasmad (–) (–)
30 (–) 30 (–) (–) (–)
31 (–) 31 (–) (–) (–)
32 (–) 32 (–) (–) (–)
33 Rhinovirusa 33 (–) (–) (–)
34 (–) 34 Rhinovirus & enterovirusa,b (–) (–)
35 Parvovirusd 35 (–) (–) (–)
36 GASb 36 (–) (–) (–)
37 Rhinovirusa 37 (–) (–) (–)
38 Rhinovirusa 38 Adenovirusa & E.colie (–) (–)
39 Rhinovirusa 39 (–) (–) (–)
40 (–) 40 Bocavirusa (–) (–)
41 (–) 41 (–) (–) (–)
42 (–) 42 (–) (–) (–)
43 (–) 43 (–) (–) (–)
44 (–) 44 (–) (–) (–)
(Continued)
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45 (–) 45 (–) (–) (–)
46 GASb 46 (–) (–) (–)






















(–), Negative; (+), Positive; GAS, Group A Streptococcus; CMV, Cytomegalovirus; EBV, Epstein Barr Virus; Anti-HBc, hepatitis B core antibody; Anti-HBs, hepatitis B surface antibody.
All patients from the CoV– group were tested for SARS-COV-2 PCR and serology.
comparing PreCoV to CoV+ patients we found in CoV+ group
significantly lower leucocyte (15.5 × 109/L vs. 9.5 × 109/L, p <
0.001) and platelet count (423× 109/L vs. 174× 109/L, p< 0.001)
and higher terminal segment of the natriuretic atrial peptide
(NT-proBNP) (503 pg/ml vs. 4,766 pg/ml, p < 0.001), ferritin
(185 ng/ml and 476 ng/ml, p < 0.001), C-reactive protein (CRP)
(median, 10.9 vs. 18.5 mg/dl, p< 0.005), and procalcitonin (PCT)
(median, 0.85 vs. 4.54 ng/ml, p < 0.005) (Table 1, Figures 2, 3).
A positive microbiological finding other than SARS-CoV-2
was found in PreCoV, CoV+, and CoV– patients in 27, 15, and
20% of cases, respectively (Table 2).
Outcome and Treatment
Echocardiographic examinations were abnormal in PreCoV,
CoV–, and CoV+ patients in 37% (23/67), 45% (9/20), and
50% (13/26), respectively: CAL were observed in 18/23 (75%),
3/9 (33.3%), and 4/13 (39%) among those with abnormal
echocardiography, coronary aneurysms in 7/63 (11%), 2/20
(10%), and 1/26 (3.8%), left ventricular dysfunction in 1/63
(1.59%), 2/20 (10%), and 8/26 (30.8%), and pericardial effusion
in 13/23 (56.5%), 4/9 (44.4%), and 3/13 (23.1%). Left ventricular
dysfunction was the only echocardiographic finding that was
significantly higher in CoV+ than PreCoV group (p < 0.001)
and in all cases it was transient. No giant coronary artery
aneurysms were seen. A higher rate of abnormal repolarization
in electrocardiographic studies was observed in CoV+ patients
compared with PreCoV and CoV– patients (19 vs. 3% and
0%, respectively).
Treatment with IVIG was given to 95, 100, and 80% of the
PreCoV, CoV–, and CoV+ patients, respectively. The mean days
of fever onset to IVIG administration were 6 days in all groups.
A second IVIG dose was given in 14% (8/58), 20% (4/20), and
19% (4/21), and corticosteroids were given in 28.6% (18/63), 50%
(10/20), and 61.5% (16/26), respectively. Only one CoV+ and one
CoV– patient received Tocilizumab, and one patient in the CoV+
group received Anakinra.
A significantly higher number of patients were admitted to
PICU from the CoV+ 50% (13/26) vs. the PreCoV group 5%
(3/63), p < 0.001. When comparing the PreCoV to the CoV–
patients, there is still a higher non-significant number of patients
that require PICU 5% (3/63) vs. 30% (6/20). The main reason
for PICU admission in the CoV+ group was due to cardiac
dysfunction or shock. Vasoactive support was given to 3/13 (23%)
in the CoV+ group vs. 1/6 (16%) in the CoV– group and none
during the PreCoVp.
Only one patient from PreCoV had a persistent aneurysm, and
one in the CoV– is still under follow-up. No deaths were reported
(Table 3).
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Male 38 (62.3%) 18 (69.2%) 0.709 10 (50.0%) 0.478
Median age (years) (IQR) 2.55 (1.46; 3.89) 7.54 (5.36; 10.8) <0.001 3.56 (2.20; 6.37) 0.074
Non-Caucasian 18 (28.6%) 16 (64.0%) 0.005 5 (25.0%) 0.981
Clinical features
Median days of fever 7.00 (6.00; 8.00) 7.00 (6.00; 9.00) 0.483 7.00 (5.75; 8.00) 0.817
Complete KD 43 (68.3%) 7 (26.9%) <0.001 8 (40.0%) 0.019
Classical criteria
Conjunctival injection 49 (77.8%) 22 (84.6%) 0.660 16 (80.0%) 1.000
Lips and oral changes 53 (85.5%) 13 (50.0%) 0.001 16 (80.0%) 0.725
Changes in extremities 41 (66.1%) 8 (32.0%) 0.008 7 (35.0%) 0.028
Polymorphous exanthema 54 (87.1%) 21 (80.8%) 0.515 14 (70.0%) 0.094
Acute lymphadenopathy 32 (50.8%) 11 (42.3%) 0.620 7 (35.0%) 0.329
Other symptoms
Respiratory symptoms 40 (63.5%) 19 (73.1%) 0.533 13 (65.0%) 1.000
Rhinorrhea 21 (33.3%) 0 (0.00%) 0.002 2 (10.0%) 0.081
Cough 15 (23.8%) 4 (15.4%) 0.550 3 (15.0%) 0.540
Wheezing 2 (3.17%) 1 (3.85%) 1.000 1 (5.00%) 0.568
Pleural effusion 2 (3.17%) 1 (3.85%) 1.000 0 (0.00%) 1.000
Dyspnea 2 (3.17%) 1 (3.85%) 1.000 0 (0.00%) 1.000
Abnormal Chest-X-ray 6 (17.6%) 10 (38.5%) 0.131 4 (25.0%) 0.707
Musculoskeletal symptoms
Arthralgia 8 (12.7%) 1 (3.85%) 0.274 1 (5.00%) 0.680
Arthritis 8 (12.7%) 1 (3.85%) 0.274 1 (5.00%) 0.680
Myalgia 4 (6.35%) 3 (11.5%) 0.412 0 (0.00%) 0.568
Gastrointestinal symptoms 36 (57.1%) 17 (65.4%) 0.629 11 (55.0%) 1.000
Abdominal pain 21 (33.3%) 15 (57.7%) 0.059 6 (30.0%) 0.997
Nausea 4 (6.35%) 3 (11.5%) 0.412 2 (10.0%) 0.628
Vomits 23 (36.5%) 10 (38.5%) 1.000 5 (25.0%) 0.498
Diarrhea 8 (12.7%) 6 (23.1%) 0.336 4 (20.0%) 0.471
Any hepatic alteration 30 (47.6%) 14 (53.8%) 0.763 9 (45.0%) 1.000
Hypertransaminasemia 30 (47.6%) 13 (50.0%) 1.000 8 (40.0%) 0.735
Hyperbilirubinemia 4 (6.35%) 1 (3.85%) 1.000 0 (0.00%) 0.568
Hepatomegaly 4 (6.35%) 2 (7.69%) 1.000 0 (0.00%) 0.568
Cholestasis 1 (1.59%) 1 (3.85%) 0.501 0 (0.00%) 1.000
Nervous system symptoms
Headache 6 (9.68%) 3 (11.5%) 0.688 1 (5.26%) 1.000
Irritability 35 (55.6%) 1 (3.85%) <0.001 9 (47.4%) 0.271
Aseptic meningitis 2 (3.17%) 1 (3.85%) 0.328 0 (0.00%) 0.707
Genitourinary symptoms
Hematuria 4 (6.35%) 2 (7.69%) 0.680 3 (15.0%) 0.218
Sterile pyuria 13 (21.3%) 0 (0.00%) 0.015 7 (35.0%) 0.427
Shock not related with IVIG 1 (1.59%) 13 (50.0%) <0.001 4 (20.0%) 0.011
PIMS-TS criteria fulfilled – 23 (88.5%) 8 (40%)
Complete KD 7/23 (30.4%) 3/8 (37.5%)
Incomplete KD 16/23 (69.6%) 5/8 (62.5%)
MIS-C criteria fulfilled – 23 (88.5%) 9 (45%)
Complete KD 7/23 (%) 2/9 (22.2%)
Incomplete KD 16/23 (%) 7/9 (77.8%)
Cardiology examinations
Any echocardiogram alterations 23 (37.1%) 13 (50.0%) 0.376 9 (45%) 0.594
(Continued)
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p. value 2020 (CoV-)
N = 20
p. value
Coronary artery lesions 18 (75.0%) 4 (30.8%) 0.023 3 (33.3%) 0.044
Ectasia 12 (19.0%) 3 (11.5%) 0.538 2 (10.0%) 0.500
Aneurysm 7/23 (30.4%) 1/13 (7.7%)* 0.212 2/9 (22.2%) 1.000
7/63 (11.1%) 1/26 (3.85%) 0.429 2/20 (10.0%) 1.000
z score: (small) 7 (100%) 1 (100%) 2 (100%) .
Persistent Aneurysm 1/7 (14.3%) 0 (0.00%) 0.250 0 (0.00%) 0.417
Systolic dysfunction Left V. 1/63 (1.59%) 8/26 (30.8%) <0.001 2/20 (10.0%) 0.143
Pericardial effusion 13/23 (56.5%) 3/13 (23.1%) 0.083 4/9 (44.4%) 0.699
Repolarization alterations 2 (3.17%) 5 (19.2%) 0.021 0 (0.00%) 1.000
Pharmacotherapy
Days from fever to IVIG 6.00 (5.00; 8.00) 6.00 (4.00; 7.00) 0.194 6.00 (5.00; 8.25) 0.455
IVIG 1st dose 58/63 (92%) 21/26 (80.8%) 0.149 20 (100%) 0.329
IVIG 2nd dose 8/58 (13.8%) 4/21 (19.0%) 0.723 4 (20.0%) 0.492
Corticosteroids 18/63 (28.6%) 16/26 (61.5%) 0.008 10 (50.0%) 0.104
Tocilizumab 0 (0.00%) 1 (33.3%) 1.000 1 (100%) 1.000
Anakinra 0 (0.00%) 1 (14.3%) 1.000 0 –
Outcome
Admission to PICU 3 (4.92%) 13 (50.0%) <0.001 6 (30.0%) 0.006
Days in PICU 7.00 (5.50; 7.50) 4.00 (3.00; 5.00) 0.247 4.50 (2.25; 6.75) 0.362
Reason PICU admission
Myocarditis 0 (0.00%) 6 (23.1%) <0.001 1 (5.00%) 0.241
Cardiac dysfunction 0 (0.00%) 6 (23.1%) <0.001 0 –
Suspicion of Sepsis 2 (3.17%) 1 (3.85%) 1.000 0 (0.00%) 1.000
Hypotension shock 1 (1.59%) 9 (34.6%) <0.001 3 (15.0%) 0.042
Vasoactive drugs: 0 (0.00%) 3 (11.5%) 0.023 1 (5.00%) 0.241
Cardiogenic shock 0 (0.00%) 1 (3.85%) 0.292 0 -
Respiratory distress 1 (1.59%) 0 (0.00%) 1.000 0 (0.00%) 1.000
Median (interquartilic range). CoV+, SARS-CoV-2 positive patients; CoV–, SARS-CoV-2 negative patients; IQR, interquartile range; KD, Kawasaki Disease; IVIG, intravenous
immunoglobulin; Left V, Left Ventricle; MIS-C, multisystem inflammatory syndrome in children; PICU, pediatric intensive care unit; PIMS-TS, pediatric inflammatory multisystemic
syndrome temporary associated with SARS-CoV-2.
*This patient received IVIG within the first 10 days after fever onset.
DISCUSSION
To our knowledge, this is the first study to compare KD
cases prospectively recruited presenting before and during the
pandemic and that study separately the SARS-CoV-2 confirmed
positive and negative cases and compare them with pre-
pandemic patients from the preceding years.
We report a significant increase in the number of KD
cases in Spain during the SARS-CoV-2 pandemic, with an
overall 2-fold increase in cases reported as KD in the national
database and a 10–20-fold increase of cases admitted to PICU
compared to the previous 2 years. A similar study from northern
Italy found a 30-fold increased incidence (13). Despite a 2-
fold increase in the cases reported as KD in the national
database when we analyzed each case in this new context, we
find that classical KD remains similar, as the prevalence of
CoV–KD seems not to have increased. Moreover, our series
provides data strongly suggesting that even in the era of
COVID-19 some classical KD remain andmust not be considered
as PIMS.
The majority of the KD SARS-CoV-2 confirmed cases
fulfilled the PIMS-TC/MIS-C criteria; knowing case definition
was intended to be sensitive, and therefore most KD cases
are included. Albeit a positive result, detecting SARS-CoV-2
is suggestive for PIMS-TS/MIS-C, but it is not essential for
diagnosis: a likely contact with patients with COVID-19 is
enough for PIMS-TS, and MIS-C criteria include negative PCR
for SARS-CoV-2.
Clinical and laboratory features of CoV+ KD patients
resemble PIMS-TC/MIS-C and have many significant
differences from PreCoV cases. Patients with CoV+ KD
are older, have non-Caucasian predominance, more intense
inflammation, and greater myocardial injury than patients with
classical KD.
We have compared our data to other European KD series that
also looked at KD and Kawasaki-like cases presenting during the




































TABLE 4A | Patients from CoV+ cohort, indicating complete/incomplete KD and the criteria met for PIMS-TS and MIS-C diagnosis.
Patient number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26
Complete/Incomplete KD C C I I I C C * * C I C I I * I I I * I I I C I I *
Fever > 3 d x x x x x x x x x x x x x x x x x x x x x x x x x x
Rash/Conjunctivitis/Mucocutaneous inflammation
signs
x x x x x x x x x x x x x x x x x x x x x x x
Hypotension/Shock x x x x x x x x x x x x x
Myocardial dysfunction/pericarditis/valvulitis/CAA x x x x x x x x x x x x x x x x x x x x x
Coagulopathy x x x x x x x x x x x x x x
GI symptoms x x x # x x # ‡ x x x x x x x x x x x x
PCR > 5 mg/dL x x x x x x x x x x x x x x x x x x x x x x x x
PCT > 1 ng/mL x x x x x x x x x x x x x x x x x x x
No other cause x x x x x x x x x x x x x x x x x x x x x x x x x x
PIMS-TS (WHO) Yes Yes Yes Yes No Yes Yes Yes Yes Yes No Yes No Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Persistent fever x x x x x x x x x x x x x x x x x x x x x x x x x x
Persistent inflammation x x x x x x x x x x x x x x x x x x x x x x x x x x
Single or multi-organ dysfunction x x x x # x x #‡ x x x x x x x x x x x x x x x x x
Shock x x x x x x x x x x x x x
Cardiac disorder x x x x x x x x x x x x x x x x
Respiratory disorder x x x
Renal disorder
GI disorder x x x # x x #‡ ‡ x x x x x x x x x x x
Neurological disorder x x x
No other cause x x x x x x x x x x x x x x x x x x x x x x x x x x
SARS-CoV-2 + + + + + + + + + + + + + + + + + + + + + + + + + +
MIS-C (RCPCH) Yes Yes Yes Yes No Yes Yes No Yes Yes Yes Yes No Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
BP, Blood pressure; C, Complete; CAA, Coronary artery abnormalities; GI, Gastrointestinal; I, Incomplete; KD, Kawasaki disease; MIS-C, Multisystem inflammatory syndrome in children; PIMS-TS, Pediatric inflammatory multisystem
syndrome temporally associated with SARS-CoV-2; RCPCH, Royal College of Paediatrics and Child Health; WHO, World Health Organization.
*These patients didn’t meet the criteria for KD at the moment of admission, but they fulfilled the criteria for incomplete KD during admission.
#These patients complained only of mild abdominal pain.
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TABLE 4B | Patients from CoV- cohort indicating complete/incomplete KD and the criteria met for PIMS-TS and MIS-C diagnosis.
Patient number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Complete/Incomplete KD I I C C I I C * I I I I C I C I C I C C




x x x x x x x x x x x x x x x x x x x




x x x x x x x x x x x
Coagulopathy x x x x
GI symptoms x x x x x x x x x x x
PCR> 5 mg/dL x x x x x x x x x x x x x x x x x
PCT > 1 ng/mL x x x x x
No other cause x x x x x x x x x x x x x x x x x x x x
MIS-C (WHO) Yes Yes No No No No No Yes No No No No Yes No Yes Yes Yes Yes No No
Persistent fever x x x x x x x x x x x x x x x x x x x x
Persistent inflammation x x x x x x x x x x x x x x x x x x x x
Single or multi-organ dysfunction x x x x x x x x x x ‡
Shock x x x x
Cardiac disorder x x x x x x x x
Respiratory disorder x x
Renal disorder
GI disorder x x x # # x x x x ‡
Neurological disorder
No other cause x x x x x x x x x x x x x x x x x x x
SARS-CoV-2 - - - - - - - - - - - - - - - - - - - -
PIMS-TS (RCPCH) Yes Yes No No Yes No No No Yes No Yes No Yes No Yes Yes No Yes No No
BP, Blood pressure; C, Complete; CAA, Coronary artery abnormalities; GI, Gastrointestinal; I, Incomplete; KD, Kawasaki disease; MIS-C, Multisystem inflammatory syndrome in
children; PIMS-TS, Pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2; RCPCH, Royal College of Paediatrics and Child Health; WHO, World
Health Organization.
*These patients didn’t meet the criteria for KD at the moment of admission, but they fulfilled the criteria for incomplete KD during admission.
#These patients complained only of abdominal pain.
‡These patients had elevation of liver enzymes but <2 upper limit of normality.
Diagnostic criteria of inflammatory:
• MIS-C (WHO):
◦ Children and adolescents 0–19 years of age with fever > 3 days AND two of the following:
a) Rash or bilateral non-purulent conjunctivitis or mucocutaneous inflammation signs (oral, hands, or feet).
b) Hypotension or shock.
c) Features of myocardial dysfunction, pericarditis, valvulitis, or coronary abnormalities (including ECHO findings or elevated troponin/NT-proBNP)
d) Evidence of coagulopathy (by PT, PTT, elevated D-Dimers).
e) Acute gastrointestinal problems (diarrhea, vomiting, or abdominal pain).
◦ AND elevated markers of inflammation such as ESR, C-reactive protein, or procalcitonin.
◦ AND no other obvious microbial cause of inflammation, including bacterial sepsis, staphylococcal or streptococcal shock síndrome.
◦ AND evidence of COVID-19 (RT-PCR, antigen test, or serology positive), or likely contact with patients with COVID-19.
• PIMS-TS (RCPCH):
◦ A child presenting with persistent fever, inflammation (neutrophilia, elevated CRP and lymphopaenia) and evidence of single or multi-organ dysfunction (shock, cardiac, respiratory,
renal, gastrointestinal or neurological disorder) with other additional clinical, laboratory or imagining and ECG features. Children fulfilling full or partial criteria for Kawasaki disease may
be included.
◦ Exclusion of any other microbial cause, including bacterial sepsis, staphylococcal or streptococcal shock syndromes, infections associated with myocarditis such as enterovirus.
◦ SARS-CoV-2 PCR testing positive or negative.
pandemic. Table 5 summarizes data from Pouletty et al. (15),
Verdoni et al. (13), and Toubiana et al. (23).
The median PreCoV age was 2.55 years that was similar to
the CoV– group (3.56 yr) and to our retrospective data (24)
and significantly higher for CoV+ patients (7.54 yr) that was
closer in age to those reported in the PIMS-TC series (9 yr)
(5, 25) and the KD series during the pandemic (7.5–10 yr)
(13, 15, 26–28).
Historically, KD has known to have male predominance (18),
and we found a male predominance in PreCoV and in CoV+
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FIGURE 2 | Comparison of laboratory results of Kawasaki disease cases (2018–2019) vs. 2020 (CoV+).
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FIGURE 3 | Comparison of laboratory results of Kawasaki disease cases (2018–2019) vs. 2020 (CoV–).
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TABLE 5 | Summary from Kawasaki disease series during the SARS-CoV-2 pandemic.
Fernández-Cooke
et al.* Our Cohort
COVID + N = 26
Fernández-Cooke
et al.* Our Cohort
COVID – N = 20
Pouletty et al. (15)*
N = 16
Verdoni et al. (13)**
N = 10
Toubiana et al. (23)***
N = 21
Median age (years) 7.54 (5.36–10.8) 3.56 (2.2–6.37) 10 (4.7–12.5) 7.5 (3.5) 7.9 (3.7–16.6)
Gender-male n (%) 18 (69.2%) 10 (50%) 8 (50%) 7 (70%) 9 (43%)
Ethnicity
- Caucasian 9 (36%) 15 (75%) 4 (25%)‡ – 12 (29%)‡‡ (n = 42)
- Not Caucasian 16 (64%) 5 (25%) – – –
Symptoms
Fever 26 (100%) 20 (100%) 16 (100%) 10 (100%) 21 (100%)
Polymorphous exanthema 21 (80.8%) 14 (70%) 13 (81%) 8 (80%) 16 (76%)
Conjunctival injection 22 (84.6%) 16 (80%) 15 (94%) 9 (90%) 17 (81%)
Lips and oral changes 13 (50%) 16 (80%) 14 (87%) 7 (70%) 16 (76%)
Changes in extremities 8 (32%) 7 (35%) 11 (68%) 5 (50%) 10 (48%)
Cervical lymphadenopathy 11 (42.3%) 7 (35%) 6 (37%) 1 (10%) 12 (57%)
Complete KD 7 (26.9%) 8 (40%) 10 (62%) 5 (50%) 11 (52%)
Gastrointestinal symptoms 17 (65.4%) 11 (55.0%) 13 (81%) 6 (60%) 21 (100%)
Respiratory symptoms 19 (73.1%) 13 (65.0%) 2 (12%) – –
Neurological symptoms – – 9 (56%) – 12 (57%)
Musculoskeletal symptoms – – 1 (6%) 4 (40%) 2 (10%)
Imaging
Abnormal chest X-ray 10 (38.5%) 4 (25%) 5 (31%) 5 (50%) 8 (44%) (n = 18)
Blood tests
Hemoglobin (g/dL) 12.2 (11–13.3) 10.9 (10.3–11.9) – 11 (1.2) 8.6 (5.3–12.2)
Leucocytes (×109/L) 9.5 (7.4–12.8) 13.8 (8.98–21.7) 11.5 (9–14.4) 10.8 (6.1) 17.4 (5.4–42.8)
Platelets (×109/L)‡‡‡ 174 (118–250) 290 (193–423) 188 (164–244) 130 (32) 499 (78–838)
C-Reactive Protein (mg/dL) 18.5 (11.4–24.2) 14.2 (9.08–16.8) 20.7 (16.2–23.6) 25 (15.3) 25.3 (8.9–36.3)
Procalcitonin (ng/mL) 4.54 (2.56–7.63) 0.48 (0.28–3.33) – – 22.5 (0.1–448)
ESR (mm/h) 46 (11.5–61) 56 (33.2–72) – 72 (24) (n=8) –
Albumin (g/dL) 3.4 (3–3.8) 3.65 (3.3–3.92) 2.1 (1.9–2.3) 3.2 (0.3) 2.1 (1.6–3.7)
ALT (IU/L) 24 (18–44) 34 (2–69) – 119 (217) 70 (6–257)
AST (IU/L) 34 (26–56) 35 (23–46) – 87 (70) –
GGT (IU/L) 20.5 (15–46.8) 15 (13.5–66.8) – – 59 (10–205)
NT-proBNP (ng/L) 4,766 (3,046–13,596) 776 (268–1,260) BNP ng/L (4,319,
2,747–6,493)
1,255 (929) BNP ng/L (3,354,
16–16,017) (n = 18)
D-dimer (mcg/L) 2,461 (1,041–3,960) 625 (287–5,478) – 3,798 (1,318) 4,025 (350–19,330) (n
= 20)
Interleukin 6 (pg/mL) 185 (75.4–310) 82.4 (51.7–84.6) 270 (136–526) 177.1 (137.4) (n = 4) 170 (4–1,366) (n = 17)
Fibrinogen (mg/dL) 810 (518–930) 591 (523–619) – 621 (182) –
Ferritin (ng/mL) 476 (358–966) 153 (116–588) 1,067 (272–1,709) 1,176 (1,032) –
Microbiological results
SARS-CoV-2 PCR + 11 (42.3%) 0 9 (56) 2 (20%) 8 (38%)
SARS-CoV-2 serology (IgG
and/or IgM) +
21 (100%) (n = 21) 0 7/8 (87%) 8 (80%) 19 (90%) (n = 20)
Pharmacotherapy
IVIG n (%) 21 (80.8%) 20 (100%) 15 (93%) 10 (100%) 21 (100%)
Steroids 16 (61.5%) 10 (50%) 4 (25%) 8 (80%) 10 (48%)
Resistance to IVIG
(persistence of fever >36 h)
4 (19%) (n = 21) 4 (20%) 10 (62%) 10 (100%) 5 (24%)
Cardiology examinations
Abnormal echocardiography 13 (50%) 9 (47.4%) 11 (69%) 6 (60%) –
Coronary artery dilations 3 (11.5%) 2 (10%) 3 (19%) – 5 (24%)
Coronary artery aneurisms 1 (3.85%) 2 (10%) 0 2 (20%) 0
Myocarditis 6 (23.1%) 1 (5%) 7 (43.8%) 5 (50%) § 16 (76%)
(Continued)
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TABLE 5 | Continued
Fernández-Cooke
et al.* Our Cohort
COVID + N = 26
Fernández-Cooke
et al. Our Cohort
COVID – N = 20
Pouletty et al. (15)*
N = 16
Verdoni et al. (13)**
N = 10




3 (23.1%) 4 (44.4%) 4 (25%) 4 (40%) 10 (48%)
Outcome
Admission to PICU 13 (50%) 6 (30%) 7 (44%) – 17 (81%)
Shock 13 (50%) 4 (20%) 7 (44%) 5 (50%) 12 (57%)
*Median (interquartilic range).
**Results as mean (standard deviation).
***Results as median (range).
†From Europe, not indicated Caucasian.
‡‡Parents, not patients, and from Europe, not indicated Caucasian.
‡‡‡Corresponding in the different studies to:
- Cooke et al. COVID+ Platelets at admission are equal to minimum platelets.
- Cooke et al. COVID- Minimum platelets (at admission 294, 193–423).
- Pouletty et al. Minimum platelets.
- Verdoni et al. not indicated.
- Toubiana et al. not indicated.
§ Indicated ejection fraction < 55%.
ALT, Alanine Aminotransferase; AST, Aspatate Aminotransferase; ESR, Erythrosedimentation Rate; GGT, Gamma Glutamyltransferase; IVIG, intravenous immunoglobulin; KD, Kawasaki
Disease; NT-proBNP, N-Terminal proB-type Natriuretic Peptide; PICU, Pediatric Intensive Care Unit.
patients. African Americans have been affected by the COVID-19
pandemic at a disproportionately higher rate (29).
Interestingly, we found a significantly higher proportion of
non-Caucasians in the CoV+ group, which does not represent
the general Spanish population. Additionally, our retrospective
study on the same population (2011–2016) found 76% of KD
cases had European origin (24). Other studies have also found
over-representation of non-Caucasian patients in the KD series
during the pandemic (5, 15, 23) reaching in a published PIMS-
TC cohort 100% of patients (25), and this may suggest an effect
of either social and living conditions or genetic susceptibility (30).
The CoV+ group had more likely incomplete KD than in
the PIMS-TS series (5, 23, 31). This phenomenon could be
because PIMS-TC and CoV+ KD are a separate entity or
because pediatricians are more aware now and diagnose more
incomplete KD in this context. After conjunctival injection,
the most frequent classical symptom was erythematous rash
and significantly less common lips and oral changes in CoV+
patients; this was also observed in PIMS-TC patients (5, 23, 31).
No patient in the CoV+ group had sterile pyuria that is typically
observed in classical KD patients.
Respiratory symptoms were not increased in our series, and
although not significant, it was more likely to have an abnormal
chest X-ray during the pandemic as reported by Toubiana et
al. (23) (44%). Probably the small sample size in our series
does not allow us to detect significant differences. There was
an increased proportion of patients with abdominal pain in the
CoV+ group, and this symptom was widely observed in PIMS-
TC patients (5, 25). Irritability was significantly lower in the
CoV+ group, probably due to the higher median age in this
group. Shock that was not related to IVIG infusion was observed
in a significantly increased number of patients who were CoV+.
This phenomenon was also observed by the other KD pandemic
series (Table 5), probably indicating again that these patients are
on the PIMS-TC spectrum.
Surprisingly, there is an absence of reported cases of
Kawasaki-like MIS associated with SARS-CoV-2 infection in
Asian countries where the COVID-19 pandemic started, and
where the incidence of KD was the highest. It has been
hypothesized that a mutation from a European strain of SARS-
CoV-2 drives a stronger cytokine storm. Serology was more
likely to be positive than PCR in our series, supporting the
postinfectious hypothesis, because the disease appears to occur
2–4 weeks after acute SARS-CoV-2 infection or exposure.
This has also been observed in the patients with PIMS-TC
and those with heart failure in this context (23, 25–27). The
coronavirus family might represent one of the triggers of KD
as previously hypothesized (32, 33), and the SARS-CoV-2 spike
may act as a superantigen driving a cytokine storm that leads to
hyperinflammation (14, 34). A positive microbiological finding
other than SARS-CoV-2 was found in around 20–25% of the
PreCoV and CoV– patients. Some of the CoV– negative patients
could have had a different trigger despite the lockdown, but some
may have been CoV false negatives explaining why this group
has overlapping clinical and laboratory features. There were no
meaningful differences in blood results between PreCoV and
CoV– patients. Nevertheless, when comparing PreCoV to CoV+
patients, we found significantly lower leucocyte and platelet
count and higher NT-proBNP, ferritin, CRP, and PCT in CoV+
patients as found in other cohorts (13, 23). These findings are
closer to those exhibited by the PIMS-TC/MIS-C and KDSS (35)
patients than to classical KD patients. The NT-proBNP levels we
found were more in line with the Paris Kawa-COVID-19 cohort
(median 4,319 pg/mL) (15) in contrast with Belhadjer et al. that
reported 10 times higher levels (mean 41,484 pg/mL) in PIMS-TC
patients (26).
Echocardiographic examinations were abnormal in 50% of
CoV+ patients similar to other KD pandemic series (Table 5)
and higher than classical KD cases; this is probably because
many CoV+ patients presented with left ventricular dysfunction.
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CAL, defined as Z-score > 2, were observed in a third of
our patients presenting during the pandemic, but <10% had
coronary aneurysms, and this was less likely in the CoV+
group. In PIMS-TC patients, 7–12% present aneurysms (25).
Interestingly, there are at least three studies that report no
coronary aneurysms in Kawa-COVID-19 patients (15) and
PIMS-TC patients (23, 26); in absolute number, we only had
one patient in the CoV+ group with a coronary aneurysm.
Our impression is that the cases associated with SARS-CoV-2,
and although they have more cardiac involvement, it is more
likely to be left ventricular dysfunction than cardiac aneurysms,
but this needs to be studied further. It is known that older
children with KD and intense inflammation are more likely to
present withmyocarditis (36). Children with PIMS-TC have been
described to have mild to moderate heart dysfunction indicating
acute myocardial injury and recovering normal cardiac function
within a week, probably because there is inflammation and
myocardial oedema but without myocardial necrosis (31, 37).
Left ventricular dysfunction was the only echocardiographic
finding that was significantly higher in CoV+, and all cases
were transient. Abnormal repolarization was relatively frequent
in CoV+ patients in our study; this is probably linked to the
higher proportion of patients with left ventricular dysfunction.
A range of ECG abnormalities (14–60%) have been reported in
PIMS-TC patients (5, 25).
We found that while 100% of CoV– patients received IVIG,
this drops to 80% in the CoV+ patients. We think this is
because some may have been treated as PIMS-TC/MIS-C where
some clinicians gave steroids directly or they recovered with
supportive care alone. Although there are no studies yet on
the best treatment for this new entity, most groups are giving
first-line treatment with IVIG followed by steroids in some
patients ranging from 33 to 64%, and biological agents in 8–
14% (5, 23, 25, 26). A second IVIG dose was given in a similar
proportion of patients from all groups, and corticosteroids were
given more frequently in CoV+ patients, probably due to higher
inflammation markers and suspicion of PIMS-TC.
A significantly higher number of patients were admitted to
PICU from the CoV+ group. The reason for PICU admissionwas
due to cardiac dysfunction or shock resembling again PIMS-TC
rather than classical KD (5, 23, 25). The mean length of the PICU
stay was generally under a week (4–5 days) (23, 25, 27). Only one
patient from PreCoV had a persistent aneurysm, and one in the
CoV- is still under follow-up. No deaths were reported.
Our study has some potential limitations. There is a
potential recruitment bias that may have contributed to
the high number of patients with Kawasaki-like multisystem
inflammatory syndrome, as pediatricians have been more aware
due to the alerts. Antibody tests against SARS-CoV-2 were
performed by different techniques depending on the Hospital;
therefore, sensitivity and specificity have a broad range, driving
to a potential underdiagnosis. We could not calculate an overall
incidence of KD because our network did not achieve total
national coverage. Nevertheless, we think that the number
of patients collected allows us to draw conclusions, and the
prospective character of our network KAWA-RACE before and
during the pandemic places us in a privileged setting to have an
overview of what has happened in Spain.
In summary, we describe findings in the CoV+ group and
remark clinical and laboratory differences to classify them as
PIMS-TC/MIS-C and not classical KD (higher median age, non-
Caucasian predisposition, more likely incomplete presentation,
more myocardial dysfunction, less aneurysm development, more
PICU admission, and higher inflammatory markers). Whether
this is a novel entity or the same disease on different ends of the
spectrum is yet to be elucidated. However, SARS-CoV-2 seems
to be a potent trigger that in some patients leads to an aberrant
immune response, especially in older children, andmay be due to
previous infections.
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